Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non–Small Cell Lung Cancer

We studied first-line treatment of stage IV non–small-cell lung cancer in never or former/light smokers with carboplatin, pemetrexed, and bevacizumab. We found a median progression-free survival of 12.6 months, overall response rate of 47%, and median overall survival of 20.3 months. INTRODUCTION: B...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Lung Cancer
Главные авторы: Weiss, Jared M., Villaruz, Liza C., O’Brien, Jonathon, Ivanova, Anastasia, Lee, Carrie, Olson, Juneko Grilley, Pollack, Gregory, Gorman, Richard, Socinski, Mark A., Stinchombe, Thomas E.
Формат: Artigo
Язык:Inglês
Опубликовано: 2015
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4844001/
https://ncbi.nlm.nih.gov/pubmed/26774201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2015.12.006
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы